Characteristics of Long COVID-19 Syndrome

March 25, 2025 updated by: Christian Clarenbach

Long COVID Syndrom: Charakterisierung Eines Neuen Krankheitsbildes

Characterization of patients with long COVID syndrome including symptoms, medical history and persistent organ damage.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

Some people are very hesitant to recover from a COVID-19 infection and present persistent symptoms. The participants still suffer after the acute phase of the infection from shortness of breath, coughing, chest pain or fatigue. Therefore, a special interdisciplinary consultation was built. The consulatation is not only addressed to people who have been hospitalized due to COVID-19, but also to those with mild symptoms during infection. During the consultation hours, personal health data are collected that serves as the basis for this research project.

Study Type

Observational

Enrollment (Estimated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Switzerland
      • Zurich, Switzerland, 8091
        • University Hospital Zurich

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with long COVID syndrome

Description

Inclusion Criteria:

  • Long COVID syndrome
  • age >= 18 years
  • Informed consent

Exclusion Criteria:

  • none

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Long COVID
Patients with long COVID syndrome
Other: No intervention
no intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dyspnea
Time Frame: once through study completion, an average of 6 months.
modified medical research council (scale from 0 to 4). The higher the score the worse the symptoms.
once through study completion, an average of 6 months.
self-addressed Quality of life
Time Frame: once through study completion, an average of 6 months
Short form health 36 questionnaire with 8 domains, each rated from 0-100. The higher the score the better subjective quality of life.
once through study completion, an average of 6 months
Thoracic pain
Time Frame: once through study completion, an average of 6 months
assessed by medical interview (reported as yes or no)
once through study completion, an average of 6 months
Medical history
Time Frame: once through study completion, an average of 6 months
List of relevant morbidities assessed as present/not present by medical interview (e.g. respiratory, cardial, neurological, psychiatric diseases by interview and medical records)
once through study completion, an average of 6 months
Fibrosis
Time Frame: once through study completion, an average of 6 months
Assessed by chest CT, rated as present/not present
once through study completion, an average of 6 months
Myocardial damage
Time Frame: once through study completion, an average of 6 months
Assessed by myocardial damage, rated as present/not present
once through study completion, an average of 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Christian Clarenbach

Investigators

  • Study Chair: Christian F Clarenbach, MD, University Hospital Zurich, Pulmonology

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 23, 2021

Primary Completion (Estimated)

December 31, 2025

Study Completion (Estimated)

December 31, 2025

Study Registration Dates

First Submitted

March 4, 2021

First Submitted That Met QC Criteria

March 9, 2021

First Posted (Actual)

March 11, 2021

Study Record Updates

Last Update Posted (Actual)

March 30, 2025

Last Update Submitted That Met QC Criteria

March 25, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2021-00280

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

IPD will be shared on request

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Long COVID Syndrome

Clinical Trials on No intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe